Wednesday, Needham adjusted its price target for Inari Medical Inc. (NASDAQ: NARI) shares, reducing it to $57 from the previous $72, while still holding a Buy rating on the stock. The decision followed the company's first-quarter financial performance, which saw a revenue surpassing estimates but a miss on GAAP earnings per share.
Inari Medical reported a year-over-year revenue growth of 23% for the first quarter of 2024, a slight increase from the 22% growth observed in the last quarter of 2023. This growth occurred even with more challenging comparisons to previous periods.
The company's Venous Thromboembolism (VTE) segment experienced a growth of 20% in the first quarter, up from 19% in the prior quarter. However, the Emerging Therapies segment saw a deceleration, growing 185% in the first quarter of 2024 compared to 202% growth in the final quarter of 2023.
The management team at Inari Medical has raised its revenue guidance for 2024 and confirmed its expectation to achieve operating profitability in the first half of 2025. This positive outlook aligns with the company's recent performance trends.
Needham's revised price target reflects a recalibration due to a contraction in peer multiples, which has influenced the valuation of Inari Medical's shares. Despite the lowered price target, Needham's stance on the stock remains optimistic, as indicated by the maintained Buy rating.
InvestingPro Insights
As Inari Medical Inc. navigates through its financial year, real-time data from InvestingPro provides a deeper understanding of the company's current market position. With a market capitalization of $2.16 billion, Inari Medical is trading near its 52-week low, which could indicate a potential entry point for investors. The company's impressive gross profit margin of 87.67% over the last twelve months as of Q1 2024 stands out, reflecting its ability to maintain profitability on its products and services despite market challenges.
InvestingPro Tips highlight that Inari Medical operates with a moderate level of debt and has liquid assets that exceed its short-term obligations, suggesting a solid financial footing for managing its liabilities. However, analysts are cautious, as they do not anticipate the company will be profitable this year, and net income is expected to drop. With these insights, investors can weigh the potential risks and growth opportunities that Inari Medical presents.
To gain a more comprehensive understanding of Inari Medical's prospects and for access to additional InvestingPro Tips, investors can explore https://www.investing.com/pro/NARI. There are 6 more tips available that can further guide investment decisions. For those interested in a yearly or biyearly Pro and Pro+ subscription, use the coupon code PRONEWS24 to get an additional 10% off.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.